Rodriguez–Tolra J et al. – This study the safety profile and efficacy of testosterone treatment on BMD in patients with TDS. Testosterone treatment in men with TDS has a good safety profile, leads to significant improvement in lumbar spine and hip BMD, and improves symptoms, as assessed by the AMS questionnaire.
- In this 2–year prospective open–label study, patients were administered 50 mg of testosterone gel daily (adjustable after 3 months up to 75–100 mg or down to 25 mg) for 12 months, followed by treatment with 1000 mg of testosterone undecanoate every 2–3 months from months 12–24.
- Outcome measures were as follows: (i) Changes in clinical chemistry safety parameters and total testosterone, sex hormone binding globulin and calculated free testosterone (cFT) levels; (ii) Changes in Aging Males' Symptoms Scale (AMS) and International Prostate Symptom Score scores; and (iii) Changes in lumbar spine and hip BMD.
- A total of 50 men aged 50–65 years with TDS (AMS >26 and cFT <0.250 nmol/mL) took part in the study.
- There was no significant impact of testosterone on safety.
- Prostate–specific antigen and haematopoietic parameters increased significantly, although the changes were not clinically significant.
- Total and cFT increased significantly after 3 months (p < 0.001) and there were significant improvements after 3 months in AMS scores (p < 0.001).
- BMD improved significantly in L2–L4 (2.90 and 4.5%), total femur (0.74 and 3%) and trochanter (1.09 and 3.2%) at 12 and 24 months respectively.